| Literature DB >> 33615141 |
Anjani Devi Chintagunta1, Sai Krishna M1, Sanjana Nalluru1, Sampath Kumar N S1.
Abstract
The recent outbreak of coronavirus disease (COVID-19) has challenged the survival of human existence in the last 1 year. Frontline healthcare professionals were struggling in combating the pandemic situation and were continuously supported with literature, skill set, research activities, and technologies developed by various scientists/researchers all over the world. To handle the continuously mutating severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requires amalgamation of conventional technology with emerging approaches. Nanotechnology is science, engineering, and technology dealing at the nanoscale level. It has made possible the development of nanomaterials, nano-biosensors, nanodrugs, and vaccines for diagnosis, therapy, and prevention of COVID-19. This review has elaborately highlighted the role of nanotechnology in developing various detection kits such as nanoparticle-assisted diagnostics, antibody assay, lateral flow immunoassay, nanomaterial biosensors, etc., in detection of SARS-CoV-2. Similarly, various advancements supervene through nanoparticle-based therapeutic drugs for inhibiting viral infection by blocking virus attachment/cell entry, multiplication/replication, and direct inactivation of the virus. Furthermore, information on vaccine development and the role of nanocarriers/nanoparticles were highlighted with a brief outlining of nanomaterial usage in sterilization and preventive mechanisms engineered to combat COVID-19 pandemic. © Qatar University and Springer Nature Switzerland AG 2021.Entities:
Keywords: COVID-19; Diagnosis; Nanotechnology; SARS-CoV-2; Treatment; Vaccines
Year: 2021 PMID: 33615141 PMCID: PMC7883336 DOI: 10.1007/s42247-021-00178-6
Source DB: PubMed Journal: Emergent Mater ISSN: 2522-5731
Fig. 1Emerging technologies to combat COVID-19
Fig. 2Applications of nanomaterials
Nano-based vaccines against SARS-CoV-2
| Vaccine | Developer/s | Platform | Current status |
|---|---|---|---|
| mRNA-1273 | Moderna, USA and National Institutes of Health (NIH) | • mRNA-based vaccine • S protein encapsulated in lipid nanoparticles • Type: muscle injection | Phase III |
| BNT162b2 | BioNTech/Pfizer (Germany) | • LNPs combined with mRNA • Type: muscle injection | Phase III |
| Ad5-nCoV/Convidecia | Cansino Biologics (China) | • Adenovirus 5 vector containing S nanoparticles • Type: muscle injection | Phase III |
| NVX-CoV2373 | Novavax, USA | • Virus-like nanoparticle, containing S protein with adjuvant matrix | Phase III |
| UQ-CSL V451 | Viroclinics Xplore (Netherlands) | • University of Queensland molecular clamp technology, with S protein and adjuvant | Phase I |
| COVID-19 vaccine | Ufovax, USA | Single-component self-assembling protein nanoparticle | Phase I |
| COVID-19 vaccine | Janssen Pharmaceuticals, Belgium | AdVac® technology recombinant vaccine based on adenovirus vectors combined with the PER.C6® cell line | Pre-clinical |
| COVID-19 vaccine | Sanofi and Translate Bio (USA) | LNPs loading mRNA encoding SARS-CoV-2 functional proteins | Pre-clinical |
| DPX-COVID-19 | IMV, Canada | LNPs formulated with DPX platform, containing peptides epitopes from SARS-CoV-2 S protein | Pre-clinical |
| COVID-19 vaccine | CanSino Biologics with Precision NanoSystems | mRNA lipid nanoparticle vaccine | Pre-clinical |
| COVID-19 vaccine | Fudan University JiaoTong University and RNACure Biopharma (China) | LNPs loading mRNA encoding the receptor-binding domain of SARS-CoV-2 | Pre-clinical |
| COVID-19 vaccine | St. Petersburg Scientific Research Institute of Vaccines and Serums (Russia) | LNPs formulated with recombinant S protein and other epitopes | Pre-clinical |